1 Reason Compass Pathways Is Worth a Second Look This Month

Compass Pathways is developing COMP360, a synthetic psilocybin treatment for treatment-resistant depression. With positive Phase 3 trial results and an FDA Commissioner's National Priority Voucher, the company expects to complete its FDA application by end of 2026, potentially leading to approval in early 2027. Analysts project 95% upside from current $12 share price to average target of $23.75.